This novel formulation not only significantly improved tocotrienol uptake by transferrin-expressing tumor cells but also improved the in vitro therapeutic efficacy of free tocotrienol from 17- to 72-fold depending on the cell line. The gene discussed is TF; the disease is neoplasm.